Jump Financial’s Denali Therapeutics DNLI Stock Holding History

Jump Financial’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-40,608	Closed	-$670K	–	2004
2025 Q4	$670K	Sell	40,608 -125,791	-76%	-$2.12M	0.01%	1158
2025 Q3	$2.42M	Buy	+166,399	New	+$2.39M	0.03%	671
2023 Q4	–	Sell	-19,787	Closed	-$408K	–	1883
2023 Q3	$408K	Buy	+19,787	New	+$502K	0.02%	1123
2023 Q2	–	Sell	-93,371	Closed	-$2.15M	–	1880
2023 Q1	$2.15M	Buy	+93,371	New	+$2.57M	0.09%	342
2022 Q4	–	Sell	-102,152	Closed	-$3.13M	–	1669
2022 Q3	$3.13M	Buy	102,152 +87,855	+614%	+$2.86M	0.12%	244
2022 Q2	$420K	Buy	+14,297	New	+$375K	0.02%	923
2022 Q1	–	Sell	-10,203	Closed	-$455K	–	1627
2021 Q4	$455K	Buy	+10,203	New	+$483K	0.03%	695
2021 Q2	–	Sell	-14,300	Closed	-$817K	–	1146
2021 Q1	$817K	Buy	14,300 +11,100	+347%	+$743K	0.08%	270
2020 Q4	$268K	Buy	+3,200	New	+$193K	0.05%	644

Other funds holding DNLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Jump Financial's DNLI Position: Q1 2026 in Review

Jump Financial sold out of Denali Therapeutics (DNLI) in Q1 2026, closing a stake of 40,608 shares — an estimated $670K sold.

Jump Financial first reported a position in DNLI in Q4 2020 and held it in 9 quarters. The position peaked at $3.13M in Q3 2022. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

Jump Financial reported no remaining Denali Therapeutics position as of Q1 2026 after selling out during the quarter.
Jump Financial sold 40,608 Denali Therapeutics shares in Q1 2026, an estimated $670K.
Jump Financial first reported a position in Denali Therapeutics in Q4 2020 and held it in 9 quarters.
Jump Financial's Denali Therapeutics position peaked at $3.13M in Q3 2022.
269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Jump Financial's 13F filing for Q1 2026, filed 14 May 2026.